OncLive TV

Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.

C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Stephen V. Liu, MD, discusses updated data from the phase 2 TRUST-II trial investigating taletrectinib in ROS1-positive non–small cell lung cancer.

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

Sandip P. Patel, MD, discusses the Immune Profile Score and how it may be used to inform decisions with immune checkpoint inhibitor therapy in solid tumors.

Suresh Senan, MRCP, FRCR, PhD, discusses the significance of the FDA approval of durvalumab for patients with limited-stage small cell lung cancer.

Alison Schram, MD, discusses the FDA approval of zenocutuzumab in non–small cell lung cancer and pancreatic cancer harboring NRG1 fusions.

Shaji Kumar, MD, discusses notable therapy considerations for multiple myeloma following the 2024/early 2025 NCCN guidelines update.

Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

Guru P. Sonpavde, MD, discusses the AMBASSADOR trial of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma.

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Shaji Kumar, MD, discusses 2024 updates made to the NCCN guidelines for multiple myeloma treatment, as well as the first 2025 updates.

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.